Theravance Biopharma

closed close
Biotech

Theravance halves head count, ends R&D work after ph. 3 fail

Theravance Biopharma will lay off 50% of its workforce, end all R&D work and scrap a blood pressure disorder drug that failed a crucial phase 3 test.
Will Maddox Mar 3, 2026 12:08pm
boxing punch blow hit punching bag fight

Theravance takes another blow, cuts staff again in regroup

Feb 28, 2023 4:31am